Industry Newsgenome editingprecision genetic drugsbeam therapeuticsanalyst coverage
Beam Therapeutics Receives Broker Price Target Boosts
|
7.1
On Jan. 7, 2026, Bernstein kept an Outperform rating for Beam Therapeutics and raised its price target from $37 to $41 after a favorable Alpha-1 Antitrypsin Deficiency (AATD) regulatory update. On the same day UBS initiated coverage with a neutral rating and a $28 target, citing improving biotech fundamentals; revised AATD data expected in Q1 2026 could act as a catalyst.
Scoring Rationale
Broker ratings and upcoming Q1 AATD data drive relevance; limited novelty beyond routine analyst coverage constrains novelty.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
